-
公开(公告)号：WO2020212267A1
公开(公告)日：2020-10-22
申请号：PCT/EP2020/060252
申请日：2020-04-09
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
Inventor： STAVER, Ruslan , SIMON, Michaelis
IPC: C07D213/73 , A61K31/44 , A61P21/00
Abstract: The present invention relates to a crystalline form of amifampridine phosphate having an irregular or plate-like, not needle-like crystal habit and to a process for its manufacture.
-
公开(公告)号：WO2019073062A1
公开(公告)日：2019-04-18
申请号：PCT/EP2018/077953
申请日：2018-10-12
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
Inventor： RALLABANDI, Bala Ramesha Chary , PRATHAP, Vamshi Ramana , GOLLAPUDI, Krishna Mohan , VELUSAMY, Bala Subramanian , BANDLA, Srimannarayana , SCHLEHAHN, Hendrik , RUCHATZ, Dieter
IPC: A61K9/20 , A61K31/225 , A61K31/41
CPC classification number: A61K9/2009 , A61K9/2095 , A61K31/216 , A61K31/41 , A61K2300/00
Abstract: The present invention relates to a tablet for oral administration containing valsartan and sacubitril, preferably as sodium salts or as a complex of valsartan disodium and sacubitril monosodium, preferably LCZ696. The tablet is prepared by dry-granulation or direct compression and contains a mesoporous inorganic stabilizer, e.g. mesoporous silica (Syloid®).
-
公开(公告)号：WO2014096464A1
公开(公告)日：2014-06-26
申请号：PCT/EP2014/000006
申请日：2014-01-06
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) , MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH
Inventor： FLEMMING, Jens , PETERS, Harm , BRANDT, Andreas , WILL, Heiner , MENSONIDES-HARSEMA, Marguérite M.
CPC classification number: A61K31/42
Abstract: Die vorliegende Erfindung betrifft eine erfindungsgemäße pharmazeutische Zusammensetzung mit 14 bis 17,5 mg Leflunomid hergerichtet als Einzeldosis und deren Verwendungen.
Abstract translation: 本发明涉及含有作为单次剂量来制备14至17.5毫克来氟米特本发明，并且它们的用途的药物组合物。
-
公开(公告)号：WO2013189596A1
公开(公告)日：2013-12-27
申请号：PCT/EP2013/001807
申请日：2013-06-19
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG)
Inventor： BECKER, Stefan , EILITZ, Uwe , GÖTHE, Gunnar
CPC classification number: C08G73/02 , A61L12/145 , C08G73/0226
Abstract: The present invention relates to a method for the preparation of polyquaternium-1, wherein an aprotic polar solvent is used as the reaction medium, and a solid polyquaternium-1 having a low degree of polydispersity.
Abstract translation: 本发明涉及一种制备聚季铵盐-1的方法，其中使用非质子极性溶剂作为反应介质，并且具有低分散度的固体聚季铵盐-1。
-
公开(公告)号：WO2013075822A1
公开(公告)日：2013-05-30
申请号：PCT/EP2012/004817
申请日：2012-11-21
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) , AMW GMBH
Inventor： SAHR, Florian , LANG, Susanne , RYBACH, Simon
IPC: A61K31/381 , A61K9/70 , A61P25/16 , A61P25/14 , A61P25/28
CPC classification number: A61K31/381 , A61K9/7053
Abstract: The present invention relates to an inventive transdermal therapeutic system (TTS) comprising rotigotine and a pharmaceutically acceptable adhesive comprising styrene butadiene block copolymer, an inventive matrix with extended release of rotigotine suitable for a TTS, an inventive production method for an inventive matrix or a respective TTS comprising rotigotine, as well as uses of the inventive matrix as well as the inventive TTS for the treatment, alleviation and/or prophylaxis of a Parkinson's disease, a Parkinson Plus Syndrome, a depression, a Restless Legs Syndrome, loss of dopaminergic neurons and/or pain.
Abstract translation: 本发明涉及包含罗替戈汀和药学上可接受的粘合剂的本发明的经皮治疗系统（TTS），其包含苯乙烯丁二烯嵌段共聚物，本发明的具有适用于TTS的罗替戈汀释放的基质，本发明的用于本发明的基质的制备方法或相应的 包含罗替戈汀的TTS，以及本发明的基质以及本发明的TTS用于治疗，缓解和/或预防帕金森病，帕金森综合征，抑郁症，不宁腿综合症，多巴胺能神经元的丧失和 /或疼痛。
-
Patent Agency Ranking
公开(公告)号：WO2010043376A1
公开(公告)日：2010-04-22
申请号：PCT/EP2009/007347
申请日：2009-10-13
Applicant: ALFRED E. TIEFENBACHER GMBH & CO. KG , HUAHAI , JUNQING, Peng , SHILIN, Zhou , HUIYAN, Gao , GONGYUN, Hu
Inventor： JUNQING, Peng , SHILIN, Zhou , HUIYAN, Gao , GONGYUN, Hu
CPC classification number: A61K9/5084 , A61K9/1688 , A61K9/2054 , A61K31/41 , A61K31/549 , A61K45/06 , A61K2300/00
Abstract: Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung einer Valsartan enthaltenden Tablette sowie ein Wirkstoffgranulat, das ausschließlich aus Valsartan oder einem pharmazeutisch verträglichen Salz davon und gegebenenfalls einem anderen Wirkstoff besteht, und dessen Verwendung in der Herstellung der Tablette.
Abstract translation: 本发明涉及一种用于制备含有缬沙坦片剂以及作为活性成分的颗粒剂，其由完全缬沙坦或其药学上可接受的盐和任选的另一种活性物质，其在片剂的制备中使用的。
-
公开(公告)号：WO2015189778A1
公开(公告)日：2015-12-17
申请号：PCT/IB2015/054374
申请日：2015-06-10
Inventor： BERTOLINI, Giorgio , BIAGGI, Cinzia , FERRANDO, Ilaria , RUCHATZ, Dieter , SCHLEHAHN, Hendrik
IPC: A61K9/14 , A61K9/48 , A61K31/165 , A61P25/24
CPC classification number: A61K9/143 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/165
Abstract: The present invention relates to a new agomelatine composition, particularly agomelatine in solution which isadsorbed on an inert carrier or directly formulated. Another subject-matter of the invention is a solid form made of an agomelatine in solution adsorbate and a process for the preparation of said solid form as well as the use of the adsorbate and of the composition in therapy, and pharmaceutical compositions comprising the same.
Abstract translation: 本发明涉及一种新的agomelatine组合物，特别是在惰性载体上吸附或直接配制的溶液中的agomelatine。 本发明的另一个主题是由溶液吸附物中的阿格美林形成的固体形式，以及制备所述固体形式的方法以及在治疗中使用被吸附物和组合物，以及包含其的药物组合物。
-
8.发明申请TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ROTIGOTINE AND CRYSTALLIZATION INHIBITOR 审中-公开包含ROTIGOTINE和结晶抑制剂的透皮治疗系统
公开(公告)号：WO2013075823A1
公开(公告)日：2013-05-30
申请号：PCT/EP2012/004818
申请日：2012-11-21
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) , AMW GMBH
Inventor： SAHR, Florian , LANG, Susanne , RYBACH, Simon , FITZNER, Ansgar
IPC: A61K31/381 , A61K9/70 , A61P25/16 , A61P25/14 , A61P25/28
CPC classification number: A61K31/381 , A61K9/7053
Abstract: The present invention relates to an inventive transdermal therapeutic system (TTS) comprising rotigotine, a pharmaceutically acceptable adhesive comprising styrene butadiene block copolymer and a crystallization inhibitor, an inventive matrix with an extended release of rotigotine suitable for a transdermal therapeutic system, an inventive production method of a respective matrix or a respective TTS comprising rotigotine, as well as uses of the inventive matrix and the inventive TTS.
Abstract translation: 本发明涉及包含罗替戈汀的本发明的经皮治疗系统（TTS），包含苯乙烯丁二烯嵌段共聚物和结晶抑制剂的药学上可接受的粘合剂，本发明的具有适于透皮治疗系统的罗替戈汀释放的基质，本发明的生产方法 的相应基质或包含罗替戈汀的相应TTS，以及本发明的基质和本发明的TTS的用途。
-
公开(公告)号：WO2011154118A1
公开(公告)日：2011-12-15
申请号：PCT/EP2011/002758
申请日：2011-06-06
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) , RUCHATZ, Dieter , YOGANANDA, Chaitanya, Gujjar , BALA RAMESHA CHARY, Rallabandi , LAL PASAHN, Manohar
Inventor： RUCHATZ, Dieter , YOGANANDA, Chaitanya, Gujjar , BALA RAMESHA CHARY, Rallabandi , LAL PASAHN, Manohar
IPC: A61K9/20 , A61K31/554
CPC classification number: A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/554 , A61K47/36
Abstract: The present invention relates to a prolonged-release pharmaceutical composition comprising quetiapine or a pharmaceutically acceptable salt thereof, preferably quetiapine hemifumarate, and propylene glycol alginate (PGA). The present invention further relates to the use of PGA for providing prolonged-release of a pharmaceutically active ingredient from a pharmaceutical composition.
Abstract translation: 本发明涉及包含喹硫平或其药学上可接受的盐，优选倍他平平半富马酸盐和丙二醇藻酸盐（PGA）的延长释放药物组合物。 本发明还涉及PGA用于从药物组合物中延长释放药物活性成分的用途。
-
公开(公告)号：WO2011000518A1
公开(公告)日：2011-01-06
申请号：PCT/EP2010/003857
申请日：2010-06-30
Applicant: ALFRED E. TIEFENBACHER (GMBH & CO. KG) , YOGANANDA, Chaitanya, Gujjar , BODDU, Srinath , RALLABANDI, BaIa, Ramesha, Chary , PASAHN, Manohar, LaI , FITZNER, Ansgar
Inventor： YOGANANDA, Chaitanya, Gujjar , BODDU, Srinath , RALLABANDI, BaIa, Ramesha, Chary , PASAHN, Manohar, LaI , FITZNER, Ansgar
CPC classification number: A61K9/2018 , A61K9/2866 , A61K31/4545
Abstract: The present invention relates to a production process of a solid pharmaceutical composition in dosage form of a tablet comprising desloratadine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients and/or adjuvants including lactose, characterized in that a) desloratadine or the pharmaceutically acceptable salt thereof is present in a therapeutically effective amount and that b) the lactose is present as anhydrous lactose in an amount of 22 to 78 wt.-% based on the total weight of the solid pharmaceutical composition, the solid pharmaceutical composition in dosage form of a tablet obtainable by the inventive production process as well as uses thereof.
Abstract translation: 本发明涉及包含地氯雷他定或其药学上可接受的盐和一种或多种药学上可接受的赋形剂和/或佐剂（包括乳糖）的片剂剂型的固体药物组合物的制备方法，其特征在于a）地氯雷他定或药学上可接受的盐 其可接受的盐以治疗有效量存在，并且b）乳糖以固体药物组合物的总重量为基准，为22至78重量％的无水乳糖，固体药物组合物为剂型 的片剂，其可通过本发明的制备方法获得，以及其用途。
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.017 seconds)
